Top

Neuropraxis

Gepubliceerd in:

01-08-1998 | Artikelen

De toekomstige medicamenteuze behandeling van de ziekte van Alzheimer: van symptomatische naar causale therapie

Auteurs: Jan Marius, Keppel Hesselink

Gepubliceerd in: Neuropraxis | Uitgave 4/1998

Samenvatting

Proloog: een blik in de kristallen bol, de cns-farmacotherapie van de toekomst

vorige artikel De demente patiënt en zijn verzorger

Aisen, P.S, (1997). Inflammation and Alzheimer's disease: Mechanisms and therapeutic strategies. Gerontol, 43 (1-2), 143-149.

Aisen, P.S., Pasinetti. G.M. (1998). Glucocorticoids in AIzheimer.s disease. The story so far. Drugs Aging, 12 (1).1-6.

Avery. E.E.. Baker. L.D.. Asthana, S. (1997). Potential role of muscarinic agonists in AIzheimer.s disease. Drugs & Aging II (6).450-459.

Bamer. E.L.. Gray. S.L. (199.). Donepezil use in AIzheimer.s disease. Ann Pharmacother. 32 (I), 70-77.

Bodick. N.C., Offen. W.W.. Levey. A.I., Cutier, N.R., Gauthier, S.G.. Satlin. A.. Shannon, H.E.. Tollefson. G.D., Rasmussen. K., Bymaster, F.P., Hurley, D.J. Potter, W.Z.. Paul, S.M. (1997). Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer's disease. Arch Neurol54 (4).465-473.

Caligiuri, M.P.. Rockweil. E.. Jeste, D.V. (1998). Extrapyramidal side effects in patients with AIzheimer's disease treated with low-dose neuroleptic medication. Am J Geriatr Psychiat. 6 (1).75-82.

Cummings J.L.. Cyrus P.A., Bieber F. et al. (1998) Metrifonate treatment ofthe cognitive deficits of AIzheimer.s disease. Neurology. 50. 1214-1221.

Cummings. J.L., Kaufer. D. (1996). Neuropsychiatric aspects of AIzheimer.s disease -the cholinergic hypothesis revisited. Neurology, 47 (4). 876-883.

Hallak. M., Giacobini. E. (1987). A comparison of the effects of two inhibitors on brain cholinesterase. Neuropharmacol., 26 (6), 521-530.

Hallak. M.. Giacobini. E. (1989). Physostigmine, tacrine and metrifonate: the effect of multiple doses on acetylcholine metabolism in rat brain. Neuropharmacol. 28 (J). 199-206.

Kaufer. D.I.. Cummings. J.L.. Christine, D.. Bray. T.. Castellon. S.. Masterman. D., MacMillan. A.. Ketchel. P.. DeKosky. S.T. (1998). Assessing the impact ofneuropsychiatric symptoms in AIzheimer.s disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc. 46 (2), 210-215.

Keppel Hesselink. J.M. (1998). The internet: pandora.s box containing smart drugs. Germ J Psychiat. I. 10-14.

Le Bars. P.. L.. Katz, M.M.. Berman. N.. Itil. T.M., Freedman. A. M., Schatzberg. A.F. (for the North American EGb Study Group) (1997). A Placebo-Controlled. Dubb1e-blind. Randomized Trial of an Extract of Ginkgo Biloba for Dementia. JAMA. 278. 1327-1332.

Lippiello. P.M., Bencherif. M., Gray. J.A.. Peters. S., Grigorayn. G., Hodges. H.. Collins, A.C. (1996). RJR-2403 -A Nicotinic Agonist with CNS Selectivity .2. in-vivo characterization. J Pharmacol Experim Therap. 279 (J). 1422-1429.

Loudon, J.M.. Bromidge, S.M.. Brown. F.. Clark, M.S.G.. Hatcher. J.P.. Hawkins. J.. Riley. G.J.. Noy. G.. Orlek. B.S. (1997). SE 202026: A novel muscarinic partial agonist with functional selectivity for M-l receptors. J Pharmacol Exper Therap. 283 (J). 1059-1068.

Lynch. G., Kessler, M., Rogers, G.. Ambrosingerson. J.. Granger, R.. Schehr. R.S. (1996). Psychological effects of a drug that facilitates brain ampa receptors. Intem Clin Psychopharmacol. II (I), 13-19.

Meyer, R.C., Knox, J., Purwin, D.A., SpangIer, E.L., Ingram, D.K. (I998). Combined stimulation of the glycine and polyamine sites of the NMDA receptor attenuates NMDA blockade induced leaming deficits of rats in a I4-unit T -maze. Psychopharmacol, 135 (3), 290-295.

Mimori, Y ., Nakamura, S., Yukawa, M. (I997). Abnormalities of acetylcholinesterase in Alzheimer's disease with special reference to effect of acetylcholinesterase inhibitor. Behav Brain Res 83 (I-2), 25-30.

Morris J .C., Cyrus P .A., Orazem J. et al. (I998). Metrifonate benefits cognitive, behavioral and global function in patients with Alzheimer's disease. Neurology, 50, 1222-1230.

Nicoletti, F., Casabona, G., Genazzani, A.A., Copani, A., Aleppo, G., Canonico, P.L., Scapagnini, U. (I992). Excitatory amino acids and neuronal plasticity: modulation of AMPA receptors as a novel substrate for the action of nootropic drugs. Funct Neurol, 7 (5), 413-422.

Panula, P., Rinne, J., Kuokkanen, K., Eriksson, K.S., Sallmen, T., Kalimo, H., Relja, M. (I998). Neuronal histamine deficit in Alzheimer's disease. Neuroscience 82 (4),993-997.

Riekkinen, P. Jr., Schmidt, B.H., Stefanski, R., Kuitunen, J., Riekkinen, M. (I996). Metrifonate improves spatial navigation and avoidance behaviour in scopolaminetreated, medial septum-Iesioned and aged rats. Europ J Pharmacol, 309, 121-130.

Schneider, L.S., Olin, J.T. (I994). Overview of clinical trials ofhydergine in dementia. Arch. Neurol., 51 (8), 787-798.

Sano, M., Emesto, C., Thomas, R.G., Klauber, M.R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C.W., Pfeiffer, E., Schneider, L.S., ThaI, L.J. (for the Members of the Alzheimer's Disease Cooperative Study) (I997). A Controlled Trial of Selegiline, AlphaTocopherol, or Both as Treatrnent for Alzheimer's Disease. NEJM, 336, 1216-1222.

Stewart, W.F., Kawas, C., Corrada, M., Metter, E.J. (I997). Risk of Alzheimer's disease and duration of NSAID use. Neurology, 48 (3), 626-632.

Tapiola, T., Overmyer, M., Lehtovirta, M., Helisalmi, S., Ramberg, J., Alafuzoff, I., Riekkinen, P., Soininen, H. (I997). The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease. Neuroreport, 8 (I8), 3961-3963.

Yaffe, K., Sawaya, G., Lieberburg, I., Grady, D. (I998). Estrogen therapy in postrnenopausal women: Effects on cognitive function and dementia. JAMA, 279 (9),688-695.

Titel: De toekomstige medicamenteuze behandeling van de ziekte van Alzheimer: van symptomatische naar causale therapie
Auteurs: Jan Marius
Keppel Hesselink
Publicatiedatum: 01-08-1998
Uitgeverij: Bohn Stafleu van Loghum
Gepubliceerd in: Neuropraxis / Uitgave 4/1998
Print ISSN: 1387-5817
Elektronisch ISSN: 1876-5785
DOI: https://doi.org/10.1007/BF03070931

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen

Andere artikelen Uitgave 4/1998

De demente patiënt en zijn verzorger

Behandeling van dementie: nu en in de toekomst

Omgaan met de gevolgen van dementie

De huidige medicamenteuze behandeling van de ziekte van Alzheimer